Chapter 10
Targeted Drug Delivery to Combat Antibacterial Drug Resistance

Nitin Pandey
https://orcid.org/0009-0006-4771-9030
Integral University, India

Kuldeep Singh
Integral University, India

Shom Prakash Kushwaha
https://orcid.org/0000-0002-9844-400X
Integral University, India

Arun Kumar
https://orcid.org/0000-0002-6323-7377
Integral University, India

Mohammad Khalid
College of Pharmacy, Prince Sattam Bin Abdulaziz University, Saudi Arabia

Ahsan Ahmed Khan
Integral University, India

Maaz Khan
Integral University, India

ABSTRACT

In targeted drug delivery, antibiotics are precisely delivered to infection areas using nanoparticles and carrier systems, increasing effectiveness, lowering side effects, and causing the least amount of damage to the microbiota. By increasing local antibiotic

DOI: 10.4018/979-8-3693-1540-8.ch010

concentrations, releasing antibiotics selectively depending on bacterial indicators, and using synergistic combination treatments, this approach combats antibacterial resistance. Diagnostics, real-time monitoring, and responsive medication delivery are all combined on multifunctional platforms made possible by nanotechnology. Though problems like biocompatibility and regulatory barriers still exist, recent research has shown promise both in vitro and in vivo. Targeted drug delivery, subject to additional study and invention, offers a method to increase antibiotic effectiveness while tackling resistance. It promises to improve the management of infectious diseases. Targeted distribution can address a variety of problems related to antibacterial resistance.

INTRODUCTION

Anti-bacterial drug resistance is a significant public health concern, compromising the effectiveness of traditional antibiotics. In the past century, antibiotics have been essential to saving countless lives. Antimicrobial resistance has unfortunately become a serious global public health concern due to the overuse and inappropriate use of antibiotics. To combat this challenge, targeted drug delivery presents a hopeful approach by delivering antibiotics exclusively to bacterial pathogens. This approach is designed to overcome antibacterial drug resistance. Modern medicine places a lot of emphasis on drug delivery, which is the process of delivering pharmaceuticals into the body in order to produce the intended therapeutic effect. The goal is to optimize the administration of medications in order to assure their efficacy, safety, and patient compliance. It encompasses a wide range of techniques, formulations, technologies, and procedures. Instead of allowing therapeutic chemicals to spread across the entire body or organ, targeted drug delivery involves delivering them selectively to a specific spot within the body (Zhang et al., 2021). The goal of this strategy is to maximize the drug's therapeutic effects while reducing any potential negative side effects that could arise from its wider distribution. To overcome the antibacterial resistance, prompt action is required to counter the threat posed by the growing bacterial resistance. Antimicrobial stewardship programs (ASPs) have regularly demonstrated efficacy in improving antimicrobial prescribing practices. These initiatives can successfully combat antimicrobial resistance and maintain the efficacy of currently used antimicrobial therapies (Cole et al., 2019).

Principle and Application of Target Drug Delivery

Drug targeting is a technique used in pharmaceutical and medical research to increase the therapeutic efficacy of medications while reducing side effects. The

Figure 1. General Principles Related to Drug Distribution in Targeted Drug Delivery

fundamental concept is to target the medicine to a specific area of the body, such as an organ, tissue, or kind of cell, where its therapeutic effect is most required. This may be accomplished using a variety of techniques and strategies, including the employment of specialized carriers and delivery systems.

The main goal of drug targeting is to maximize the medication's concentration at the desired target location while limiting the concentration of the drug in unintended areas. This idea has advantages like improving therapeutic effects and lowering negative effects brought on by numerous things including multitarget interactions, greater dosages, and unexpected concentrations (Kurtz and Schiffer 2021).

The use of tailored medication delivery has substantial effects on several medical and healthcare specialties. There are some applications which are in Cancer Treatment, Neurological Disorder, Cardiovascular Disease, Inflammatory Conditions, Gene Therapy, Infectious disease, Pain Management, Diabetes, Vaccination, Personalized medicines, Aesthetic Medicines, Ophthalmology, Bone Disorder, Organ Transplantation and HIV/AIDS.

These applications demonstrate the adaptability and potential influence of tailored medicine delivery in contemporary healthcare. This strategy can improve treatment outcomes and patient experiences for a variety of medical illnesses by precisely concentrating therapeutic molecules where they are required (Tuguntaev, et al., 2017).

Figure 2. An overview of intrinsic resistance mechanisms is depicted in the image. Penicillin-binding protein (PBP) is the target of β-lactam antibiotics, as seen in this example. Via a membrane-spanning porin protein, antibiotic A can enter the cell, get to its target, and stop the creation of peptidoglycans. Similar to antibiotic A, antibiotic B may also enter the cell through a porin, but it is effectively eliminated by efflux. Antibiotic C is unable to reach the target PBP because it is unable to pass through the outer membrane (Blair et al., 2015).



Anti- Bacterial Drug Resistance Mechanisms

The processes driving antibacterial antibiotic resistance must be understood. Assisting in the development of bacterial resistance include efflux pumps, target site mutations, enzyme inactivation, and biofilm formation.

- **Efflux Pump**- Numerous medicines are actively transported out of cells by bacterial efflux pumps, which also play a significant role in the inherent resistance of Gram-negative bacteria to many of the medications used to treat Gram-positive bacterial illnesses. High levels of resistance to previously therapeutically helpful antibiotics can also be conferred by overexpressed efflux pumps. While certain efflux pumps, such as Tet pumps, have a limited substrate specificity, many efflux pumps, sometimes referred to as multidrug resistance (MDR) efflux pumps, transport a variety of structurally different substrates. All bacteria include MDR efflux pumps, which have been

extensively investigated, and novel pumps that export drugs are constantly being discovered (Floyd et al., 2010). These have included MdeA in Streptococcus mutans throughout the last two years. Every bacterium has several genes on its chromosomes that encode MDR efflux pumps (Hu et al., 2012). Some of these genes have been mobilized or placed onto plasmids that may be shared by different bacteria. It was recently discovered that an IncH1 plasmid with genes coding for a new tripartite resistance nodulation division (RND) pump was recovered from a Citrobacter freundii strain that also carried the gene for the antibiotic-targeting enzyme New Delhi metallo-βlactamase 1 (NDM1)34. This is a concerning discovery since it indicates that the resistance mechanism is contagious and has the potential to spread quickly to additional infections with therapeutic relevance (Dolejska et al., 2013).

- **Target Site Mutations-** These mutations that arise in certain genes or DNA areas can in fact result in alterations in vital cellular processes, enabling bacteria to resist the effects of antibiotics. The selection pressure of antibiotics, which gives bacteria with resistance- conferring mutations an advantage in survival and the ability to proliferate, drives this process and finally results in the formation of antibiotic-resistant strains. Target site mutations arise when changes to the genetic coding of a particular area that an antibiotics targets take place. Antibiotics like linezolid, for example, prevent bacteria from synthesizing proteins by interacting with the ribosome. In this case, resistance can be brought on by changes in the targeted area. Mutation in the genes that produce the 23S ribosomal RNA are the most frequent cause of linezolid resistance in bacteria. These genes are found in several copies in bacteria, and as shown by the Minimum Inhibitory Concentration (MIH), the more mutant copies a bacterium has, the more resistant it is to linezolid. The majority of the time, many gene copies must be altered for clinically substantial resistance. The ribosomal proteins L3 and L4, which are close to the binding sites of linezolid, have also been related to mutations that cause resistance to this antibiotic (Lambert., 2005). These alterations are not just linked to resistance to linezolid; they have also been linked to resistance to other antibiotics such macrolides, and streptogramin.
- **Enzyme Inactivation-** Bacterial enzymes contribute in a variety of ways to the emergence of resistance via a number of crucial pathways. Antibiotics directly target the enzymes involved in the formation of cell walls, the synthesis of nucleic acids, and the generation of metabolites. These enzymes' structural alterations allow resistance to develop. Another approach includes the structural elements that are altered by antibiotics being modified by enzymes. Methyltransferases, for example, change ribosomal DNA.

Figure 3. Classes of Enzymes Implicated in Various Antimicrobial Drug Resistance Mechanisms



Antibiotic structures are altered or disrupted by an important enzyme cluster, which renders them inactive. The development of resistance is also aided by metabolic enzymes and enzymes that change antibiotic medical derivatives (AMDs), frequently as prodrugs (Egorov et al., 2018).

- **Bio-Film formation-** Biofilms are collections of microorganisms that develop on a variety of surfaces, including tissues, medical equipment, and water distribution systems. They are made up of bacteria that are enclosed in extracellular polymeric matrix, a naturally occurring mixture of proteins, polysaccharides, and DNA. Due of their ability to resist antibiotics, phagocytosis, and disinfectants, these biofilms are the subject of intense investigation.

Biofilms' resistance mechanisms involve the glycocalyx, which can range in thickness from 0.2 to 1.0 m and is an essential component of biofilms. Both gram-

Figure 4. The five major stages leading to the development and formation of biofilm: (1) Reversible attachments; (2) Irreversible adhesion; (3) Proliferation; (4) Maturation complete; (5) Release and spreading



positive and gram-negative bacteria have it. Electrostatic, Van der Waals, and hydrogen bond forces are all used by glycocalyx to hold the biofilm to surfaces and promote maturation. In order to enable harmful bacteria to survive challenging host environments, they adjust depending on biofilm formation. (Singh et al., 2017). Glycoproteins and polysaccharides differ in biofilm capsules depending on the environment. By collecting antibacterial compounds up to 25% of its weight, the glycocalyx matrix increases bacterial resistance to antibiotics and other antimicrobials. This matrix restricts the mobility of biocides and acts as an enzyme anchor. Enzymes provide a substrate for the degradation of biocides and safeguard the efficacy of antibacterial medicines, decreasing medication action.

Rationale for Targeted Drug Delivery

Targeted drug delivery focuses on directing drugs precisely to their designated action locations in the body to increase treatment efficacy and decrease unwanted

effects. Contrary to conventional medication delivery, which has problems with pharmaceuticals spreading broadly and affecting both healthy and sick tissues, this method has few side effects. Conventional antibiotics are ineffective against germs and can damage healthy cells. Antibiotics are intended to be sent directly to the germs they are meant to combat through a process called targeted medication delivery. Antibiotics may function better and may become once again effective as a result, causing less damage to healthy cells. Targeted medication delivery is justified by a number of major benefits, including improved therapeutic efficacy, greater therapeutic effectiveness with fewer side effects, (Taylor and Howes 1991).

A proactive move with several benefits is targeted medicine distribution. It increases the efficiency of therapies while reducing side effects by concentrating drugs at precise locations. A higher concentration of medicine reaches its intended target through improved drug bioavailability. The drug's effects are also prolonged through controlled release, which lowers the need for a dose. By adjusting therapy to each patient specifically depending on their genetic makeup and stage of the disease, personalization is used. By carefully administering treatment where it is required, this technique prevents medication resistance. In addition to the medical advantages, it can save treatment expenses by enhancing results and minimizing adverse effects. Dosing that is easier to administer encourages patient compliance and increases adherence. With its exploration of currently unreachable territory, this breakthrough opens up new therapeutic paths. In addition, its use cuts across a range of medical disciplines, promising advancement. (Annunziato 2019).

Figure 5. A variety of targeted drug delivery techniques are used to deliver medications to certain cells or tissues in the body



Targeted Drug Delivery Approaches

1. **Nanotechnology-based Approaches-** Nanoparticles provide a fantastic platform for targeted medication delivery because of their special characteristics. Antibiotics have been designed to be enclosed by metallic, polymer, and liposomal nanoparticles. Their compact size, adaptable surface characteristics, and capacity for controlled release increase medication specificity and bioavailability (Yeh et al., 2020).
2. **Antibody-guided Therapies:** Antibiotics may now be delivered directly to bacteria because of monoclonal antibodies, which have a very accurate targeting capability. Antibodies can direct antibiotics toward specific targets, minimizing exposure to non-target regions and reducing the likelihood of resistance (Zurawski et al., 2020).
3. **Physical Targeting:** In this technique, the medication distribution is guided or amplified by external forces or devices to a specific spot. In the case of magnetic medication delivery, magnetic nanoparticles are used as carriers and are guided to the target by an external magnetic field. When ultrasonic waves increase cell membrane permeability or disturb carriers, medicines are released. This method of drug administration is known as ultrasound-mediated drug delivery (Pattni et al., 2015).
4. **Ligand-based Targeting:** Natural or synthetic bacterial-specific ligands offer a tailored method of medication delivery. These ligands adhere to bacterial surfaces and facilitate pathogens' absorption of drugs. Ligand-based techniques make use of bacterial physiology to improve antibiotic uptake by bacterial cells (Srinivasarao & Low 2017).
5. **Liposome-based delivery:** Drug delivery with liposomes offers advantages including biocompatibility, low toxicity, chemical stability, and precise targeting. They provide the possibility of delivering vaccines, treating malaria, and preventing it. Liposomes perform well intravenously, but oral application is complicated by bio-membrane crossing and gastrointestinal instability. On the other hand, lipid bilayer modifications, in conjunction with ligands or polymers, improve stability and permeability for oral delivery (Gosh and De 2023).
6. **Stimulus-responsive delivery:** There are now stimuli-responsive devices for regulated medication release. They rely on biocompatible materials that may alter in response to certain stimuli, such as protonation, hydrolysis, or conformational modifications, or that are responsive to physical triggers on the basis of exogenous (temperature, magnetic fields, ultrasound, light, or electric

Figure 6. Overcoming Obstacles

pulses) or endogenous (pH shifts, enzyme levels, or redox changes) signals. Nanoscale systems control medication distribution. (Canaparo et al., 2019).

7. **Magnetic Targeting:** Magnetic forces are used to direct or concentrate particles or objects to a specific spot by interacting with external magnetic fields. Magnetic targeting is a technology utilized in industries like medicine and materials research. Diverse scientific disciplines, including medication delivery, environmental cleaning, biotechnology, material science, and navigation, are working together to find creative solutions in the fight against antibacterial drug resistance. To efficiently target antibiotics against bacteria with resistance, medicine is advancing medication delivery. The spread of drug-resistant pathogens is halted by environmental remediation using magnetic targeting. New antimicrobial substances and diagnostic tools are created via biotechnology. Modern medicinal materials are developed by material scientists. For containment, navigation monitors the propagation of resistant strains. These cross-disciplinary initiatives are essential in the fight against antibacterial antibiotic resistance (Price et al., 2018).

Overcoming Challenges

In the fight against antibacterial drug resistance, a comprehensive strategy is being undertaken to solve the difficulties of targeted medication delivery. Making precise medication delivery systems like nanoparticles and liposomes through the use of nanotechnology is required for this. The stability and solubility of the drugs are enhanced by these systems, and controlled release at infection sites is made possible. In order to identify particular strains or resistance mechanisms, bacterial sensing technologies are also being developed. They limit exposure to non-resistant strains by only releasing antibiotics when antibiotic resistance is present (Lai et al., 2022).

Strategies for targeted drug delivery have difficulties with scalability, immunological reactions, and stability. Improved nanoparticle stability and functionalization, reduced immunogenicity, and improved ligand-receptor interactions are the main goals in the quest to increase their efficacy. Additionally, in order to attack resistance from a variety of angles, combination treatments are being used. These therapies include a number of antibiotics or medications with various modes of action. Modern biomaterials ensure biocompatibility, biodegradability, and regulated drug release when used as drug delivery vehicles, improving stability and lowering the possibility of resistance development. https://www.ncbi.nlm.nih.gov/books/NBK190333/.

Parallel to this, specific delivery systems are being created to identify and bind to certain bacterial surface receptors or indicators, ensuring that antibiotics are delivered specifically to infection areas. Techniques from genetic engineering are used to alter microorganisms, increasing their susceptibility to antibiotics or improving medication absorption (Yao et al., 2023).

Surveillance systems are put in place to keep tabs on the incidence of bacteria resistant to antibiotics and to spot new patterns of resistance. This information directs the creation of new medications and helps inform treatment plans. Additionally, patient education programs seek to encourage prudent antibiotic use by reducing abuse and improper usage, both of which fuel resistance.

Preclinical and Clinical Studies

Targeted medication delivery in animal models has shown potential in preclinical research. These studies have shown beneficial outcomes, such as increased antibacterial efficacy and decreased toxicity. The foundation for clinical application has been laid by these positive findings. The usefulness and safety of these approaches in humans are being clarified by a large number of clinical investigations.

The development and evaluation of targeted drug delivery systems for antibacterial treatment must go through critical preclinical and clinical study phases. The

Figure 7. Advantages of Preclinical and Clinical Studies



main objective of preclinical investigations is to use animal models of infection to investigate the pharmacokinetics, pharmacodynamics, toxicity, and efficacy of various drug delivery methods. These investigations are crucial for perfecting the design and formulation of nanocarriers as well as figuring out the ideal dose, route of administration, and frequency. Preclinical research also provides important information about the mechanisms of action and resistance of the targeted drug delivery systems. (World Health Organization. 2022). 2021 antibacterial agents in clinical and preclinical development: an overview and analysis.

Clinical trials can also evaluate the effects of certain drug delivery methods on vital clinical outcomes, such as cure rates, relapse rates, death rates, quality of life, and cost-effectiveness.

It is impossible to overstate the importance of preclinical and clinical investigations in the context of targeted medication delivery to address antibacterial drug resistance. These studies are crucial in providing scientific support and obtaining regulatory permission for the translation of novel drug delivery systems from laboratory research to useful clinical applications. Additionally, they are essential in determining the potential benefits and limitations of targeted drug delivery systems when used with different infection types and patient demographics. Researchers and developers may ensure the security, reliability, and efficacy of targeted drug delivery systems for antibacterial treatment through thorough preclinical and clinical research (Walesch et al., 2023).

Preclinical and clinical studies are required for the development of customized drug delivery systems to fight antibacterial antibiotic resistance. In order to develop more effective and individualized treatments for bacterial infections resistant to various antibiotic classes, these studies are critical for obtaining vital data on the safety, efficacy, and patient-specific factors. Before moving on with clinical trials, preclinical research ensures the safety and efficacy of the system by assessing toxicity, optimizing formulations, and evaluating pharmacokinetics. Clinical trials evaluate the effects on public health, track the emergence of resistance, and take into account the unique features of each patient to further optimize therapies. All together, these trials offer the proof required for regulatory clearance and make a substantial contribution to reducing antibiotic resistance and enhancing patient outcomes more broadly (Theuretzbacher et al., 2020).

FUTURE DIRECTIONS

Targeted medication delivery for the treatment of bacteria is an area that is continually developing. Innovative nanomaterials, customized healthcare, and combination medicines have the potential to provide more potent remedies for antibacterial medication resistance. Furthermore, for effectively expanding these tactics, cooperation between microbiologists, pharmacologists, and engineers is essential (Spellberg, et al., 2013).

New Approaches to the Crisis of Antibiotic Resistance

Table 1. Minimizing Resistance and Infection

Prevention	Status
• Hospital rooms that "self-clean," which are disinfected automatically via misting, vapor, radiation, etc. • Enhanced, noninvasive breathing techniques, regenerative tissue technologies, and novel medication delivery systems to replace IV catheters are just a few examples. • Reducing admissions to hospitals and skilled nursing institutions through population health and health care system improvements. • Specialized vaccinations to stop diseases caused by resistant bacteria.	• Some are marketed, but they need clinical testing, therefore further research is needed. • Conceptual and structural phases. • Stage of implementation research. • Therapeutic and fundamental research stage.

Table 2. Maintaining Accessible Medicines in use While Reducing Resistance

Prevention	Status
• Data on antibiotic usage that is publicly reported and used as a standard for funding. • Making quick diagnostics and biomarker testing available and funding for them to allow for the proper administration of antibiotics. • Removal of the use of antibiotics to aid in the development of livestock. • Enhanced chemical or biological breakdown of antibiotics in trash; new waste-treatment techniques. • Research to determine the shortest effective antibiotic regimens for illnesses	• To design and implement policy, action is required. • Policy action and fundamental research are required. • Suggested legislation. • Approaching clinical trials in one way. • A few trials were concluded.

Table 3. Creating Remedies Addressing Host Targets

• **Creating remedies addressing host targets rather than microbial targets to prevent resistance-inducing selective pressure** Proof-of-concept stage in preclinical research • Infection-related host inflammation is directly controlled (e.g., using cytokine agonists or antagonists, PAMP receptor agonists) • Host nutrient retention to block microbial nutrient availability. • Antibiotics that inhibit microbial growth.
• **Developing microbe-attacking drugs with Less resistance-inducing potential,** Proof-of-concept stage in preclinical research. • Immune-based treatments, such the intravenous administration of monoclonal antibodies and white blood cells that destroy microorganisms. • Antibiotics or biologic medications that change how germs produce sickness or inflammation rather than killing them.

ETHICAL AND SAFETY CONSIDERATIONS

In order to combat antibacterial antibiotic resistance, tailored drug delivery systems must be developed and implemented with the strongest ethical and safety concerns. These factors guarantee that the treatment is efficient, reduces patient damage, and complies with ethical standards. Regarding anti-infection therapy, there is a range of possibilities from traditional to innovative approaches. Combining cutting-edge discoveries like antimicrobial peptides and nanotechnology with age-old therapies like homeopathy, herbal medicine, and lifestyle changes like sunshine or fresh air exposure provide a variety of therapeutic approaches, but when it comes to using novel or questionable medicines, especially for terminal diseases, a huge ethical consideration becomes apparent (Littmann et al., 2015), There are questions regarding the effectiveness, safety, and even toxicity of some of these alternative medicines, even though they frequently lack rigorous scientific confirmation through blinded randomized trials. Even though these treatments have been used historically in certain situations, determining their efficacy using conventional research procedures poses

difficulties. For example, performing double-blind clinical studies for therapies like exposure to fresh air offer hurdles. Still, there is a rising interest in investigating these "old wives' remedies" within the context of ethical inquiry due to growing concerns around antibiotic resistance. In an attempt to combat the worldwide problem of antibiotic resistance, scientists are currently looking at the efficacy and safety of complementary therapies (Kållberg et al., 2023, (Parsonage et al., 2017).

CONCLUSION

Antibiotic resistance may be combated in a number of ways, including using targeted medication delivery techniques. By delivering antibiotics precisely where they are required, they increase antibiotic efficacy while reducing the likelihood that bacteria may evolve resistance. This method not only improves the course of therapy but also lessens adverse effects, enhancing patient wellbeing. By tackling a critical global health issue, targeted distribution gives fresh promise in the struggle against bacterial infections. The development of antimicrobial therapies depends on continuing study, meticulous analysis, and cutting-edge methods. In order to improve medication delivery methods, scientists are investigating nanoparticles, intelligent materials, and cutting-edge biotechnology. Comprehensive testing is essential for ensuring product efficacy and safety. We can maintain our lead in the fight against antibiotic resistance by developing these solutions, ensuring that antibiotics continue to be useful for years to come.

REFERENCES

Annunziato, G. (2019). Strategies to overcome antimicrobial resistance (AMR) making use of non-essential target inhibitors: A review. *International Journal of Molecular Sciences*, *20*(23), 5844. doi:10.3390/ijms20235844 PMID:31766441

Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. (2015). Molecular mechanisms of antibiotic resistance. *Nature Reviews. Microbiology*, *13*(1), 42–51. doi:10.1038/nrmicro3380 PMID:25435309

Canaparo, R., Foglietta, F., Giuntini, F., Della Pepa, C., Dosio, F., & Serpe, L. (2019). Recent developments in antibacterial therapy: Focus on stimuli-responsive drug-delivery systems and therapeutic nanoparticles. *Molecules (Basel, Switzerland)*, *24*(10), 1991. doi:10.3390/molecules24101991 PMID:31137622

Cole, K. A., Rivard, K. R., & Dumkow, L. E. (2019). Antimicrobial stewardship interventions to combat antibiotic resistance: An update on targeted strategies. *Current Infectious Disease Reports*, *21*(10), 1–10. doi:10.1007/s11908-019-0689-2 PMID:31473861

Dolejska, M., Villa, L., Poirel, L., Nordmann, P., & Carattoli, A. (2013). Complete sequencing of an IncHI1 plasmid encoding the carbapenemase NDM-1, the ArmA 16S RNA methylase and a resistance–nodulation–cell division/multidrug efflux pump. *The Journal of Antimicrobial Chemotherapy*, *68*(1), 34–39. doi:10.1093/jac/dks357 PMID:22969080

Egorov, A. M., Ulyashova, M. M., & Rubtsova, M. Y. (2018). Bacterial enzymes and antibiotic resistance. *Acta Naturae (English Ed.)*, *10*(4), 33–48. doi:10.32607/20758251-2018-10-4-33-48 PMID:30713760

Floyd, J. L., Smith, K. P., Kumar, S. H., Floyd, J. T., & Varela, M. F. (2010). LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, *54*(12), 5406–5412. doi:10.1128/AAC.00580-10 PMID:20855745

Ghosh, R., & De, M. (2023). Liposome-Based Antibacterial Delivery: An Emergent Approach to Combat Bacterial Infections. *ACS Omega*, *8*(39), 35442–35451. doi:10.1021/acsomega.3c04893 PMID:37810644

Hu, R. M., Liao, S. T., Huang, C. C., Huang, Y. W., & Yang, T. C. (2012). An inducible fusaric acid tripartite efflux pump contributes to the fusaric acid resistance in Stenotrophomonas maltophilia. *PLoS One*, *7*(12), e51053. doi:10.1371/journal.pone.0051053 PMID:23236431

Kållberg, C., Mathiesen, L., Gopinathan, U., & Salvesen Blix, H. (2023). The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: A qualitative study. *Journal of Pharmaceutical Policy and Practice*, *16*(1), 1–13. doi:10.1186/s40545-023-00556-x PMID:36973761

Kurt Yilmaz, N., & Schiffer, C. A. (2021). Introduction: Drug resistance. *Chemical Reviews*, *121*(6), 3235–3237. doi:10.1021/acs.chemrev.1c00118 PMID:33757288

Lai, C. K., Ng, R. W., Leung, S. S., Hui, M., & Ip, M. (2022). Overcoming the rising incidence and evolving mechanisms of antibiotic resistance by novel drug delivery approaches–an overview. *Advanced Drug Delivery Reviews*, *181*, 181. doi:10.1016/j.addr.2021.114078 PMID:34896131

Lambert, P. A. (2005). Bacterial resistance to antibiotics: Modified target sites. *Advanced Drug Delivery Reviews*, *57*(10), 1471–1485. doi:10.1016/j.addr.2005.04.003 PMID:15964098

Littmann, J., & Viens, A. M. (2015). The ethical significance of antimicrobial resistance. *Public Health Ethics*, *8*(3), 209–224. https://www.ncbi.nlm.nih.gov/books/NBK190333/ PMID:26566395

Parsonage, B., Hagglund, P. K., Keogh, L., Wheelhouse, N., Brown, R. E., & Dancer, S. J. (2017). Control of antimicrobial resistance requires an ethical approach. *Frontiers in Microbiology*, *8*, 2124. doi:10.3389/fmicb.2017.02124 PMID:29163414

Pattni, B. S., & Torchilin, V. P. (2015). Targeted drug delivery systems: Strategies and challenges. *Targeted drug delivery: Concepts and design*, 3-38.

Price, P. M., Mahmoud, W. E., Al-Ghamdi, A. A., & Bronstein, L. M. (2018). Magnetic drug delivery: Where the field is going. *Frontiers in Chemistry*, *6*, 619. doi:10.3389/fchem.2018.00619 PMID:30619827

Singh, S., Singh, S. K., Chowdhury, I., & Singh, R. (2017). Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents. *The Open Microbiology Journal*, *11*(1), 53–62. doi:10.2174/1874285801711010053 PMID:28553416

Spellberg, B., Bartlett, J. G., & Gilbert, D. N. (2013). The future of antibiotics and resistance. *The New England Journal of Medicine*, *368*(4), 299–302. doi:10.1056/NEJMp1215093 PMID:23343059

Srinivasarao, M., & Low, P. S. (2017). Ligand-targeted drug delivery. *Chemical Reviews*, *117*(19), 12133–12164. doi:10.1021/acs.chemrev.7b00013 PMID:28898067

Taylor, P. W., & Howes, C. (1991). Rationale for targeted drug delivery. *Biotherapy (Dordrecht, Netherlands)*, *3*(1), 1–8. doi:10.1007/BF02175095 PMID:2009212

Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020). The global preclinical antibacterial pipeline. *Nature Reviews. Microbiology*, *18*(5), 275–285. doi:10.1038/s41579-019-0288-0 PMID:31745331

Tuguntaev, R. G., Eltahan, A. S., Salvi, S. S., & Liang, X. J. (2017). Drug Targeting: Principles and Applications. In Drug Delivery Approaches and Nanosystems, Volume 1 (pp. 383-415). Apple Academic Press.

Walesch, S., Birkelbach, J., Jézéquel, G., Haeckl, F. J., Hegemann, J. D., Hesterkamp, T., Hirsch, A. K. H., Hammann, P., & Müller, R. (2023). Fighting antibiotic resistance—Strategies and (pre) clinical developments to find new antibacterials. *EMBO Reports*, *24*(1), e56033. doi:10.15252/embr.202256033 PMID:36533629

World Health Organization. (2022). *2021 antibacterial agents in clinical and preclinical development: an overview and analysis*. Author.

Yao, J., Zou, P., Cui, Y., Quan, L., Gao, C., Li, Z., Gong, W., & Yang, M. (2023). Recent Advances in Strategies to Combat Bacterial Drug Resistance: Antimicrobial Materials and Drug Delivery Systems. *Pharmaceutics*, *15*(4), 1188. doi:10.3390/pharmaceutics15041188 PMID:37111673

Yeh, Y. C., Huang, T. H., Yang, S. C., Chen, C. C., & Fang, J. Y. (2020). Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: A review of recent advances. *Frontiers in Chemistry*, *8*, 286. doi:10.3389/fchem.2020.00286 PMID:32391321

Zhang, W., Hu, E., Wang, Y., Miao, S., Liu, Y., Hu, Y. III, Liu, J., Xu, B., Chen, D., & Shen, Y. (2021). Emerging antibacterial strategies with application of targeting drug delivery system and combined treatment. *International Journal of Nanomedicine*, *16*, 6141–6156. doi:10.2147/IJN.S311248 PMID:34511911

Zurawski, D. V., & McLendon, M. K. (2020). Monoclonal antibodies as an antibacterial approach against bacterial pathogens. *Antibiotics (Basel, Switzerland)*, *9*(4), 155. doi:10.3390/antibiotics9040155 PMID:32244733